Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4380MR)

This product GTTS-WQ4380MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Kidney transplant rejection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4380MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12885MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ6827MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ8994MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ5642MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ1588MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ953MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ3832MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ6307MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW